Lucius LuciDap Daprodustat 1mg

Product Information

• Product name: LuciDap Daprodustat 1mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Daprodustat
• Current strength: 1mg
• SKU: LU-ITEM-41
• Site category: anemia, other cancer

Product Summary

LuciDap Daprodustat 1mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Daprodustat is the active ingredient used for this product page. Public prescribing information for Daprodustat was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC 50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.

Reference Indications

Daprodustat is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Limitations of Use Daprodustat has not been shown to improve quality of life, fatigue, or patient well-being. Daprodustat is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months. Limitations of Use Not shown to improve quality of life, fatigue, or patient well-being. Not indicated for use: As a substitute for transfusion in patients requiring immediate correction of anemia.

Reference Dosage and Administration

The public label should be checked for the indication-specific recommended dosage. Available administration instructions note that the medicine may be taken Administer orally once daily, with or without food.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS Daprodustat increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) . Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels . No trial has identified a hemoglobin target level, dose of Daprodustat, or dosing strategy that does not increase these risks . Use the lowest dose of Daprodustat sufficient to reduce the need for red blood cell transfusions .

Common Adverse Reactions and Monitoring

Risk of Hospitalization for Heart Failure . Gastrointestinal Erosion . The safety of Daprodustat was evaluated in adults with dialysis-dependent chronic kidney disease with anemia in the ASCEND-D trial based on an on-study analysis (on and off treatment) . Patients were randomized to Daprodustat or rhEPO (epoetin alfa for patients on hemodialysis; darbepoetin alfa for patients on peritoneal dialysis). The median extent of exposure to Daprodustat and rhEPO was similar. Daprodustat was non-inferior to rhEPO on the time to first occurrence of major adverse cardiovascular events (MACE) in adults with anemia due to CKD who were on dialysis .

Drug Interactions and Special Populations

Moderate CYP2C8 Inhibitors: Reduce starting dose. CYP2C8 Inducers: Monitor hemoglobin and adjust the dose of Daprodustat as appropriate. Concomitant administration of moderate CYP2C8 inhibitors (e.g., clopidogrel) increases daprodustat exposure . Reduce the starting dose of Daprodustat by half when initiating treatment in patients on clopidogrel or a moderate CYP2C8 inhibitor except in patients whose starting dose is already 1 mg. Monitor hemoglobin and adjust the dose of Daprodustat when initiating or stopping therapy with clopidogrel or a moderate CYP2C8 inhibitor during treatment with Daprodustat . Monitor hemoglobin and adjust the dose of Daprodustat when initiating or stopping therapy with CYP2C8 inducers during treatment with Daprodustat . Pregnancy: May cause fetal harm.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Jesduvroq public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.